

Alkermes plc and Subsidiaries  
FY'22 Margin Adjustment (Unaudited)

(In millions, except margin %)	FY'22 Expectations	Adjustment*	Adjusted FY'22 Expectations
Total Revenues	\$ 1,045	\$ 260	\$ 1,305
Projected Net Loss — GAAP	\$ (195)	\$ 260	\$ 65
Projected Net Loss — Non-GAAP	\$ (15)	\$ 260	\$ 245
Projected Net Loss Margin — Non-GAAP	-1.4%	100.0%	18.8%

Projected GAAP and non-GAAP measures reflect mid-points within ranges of estimated guidance.

\*This adjustment reflects the addition of royalty revenue related to INVEGA HAFYERA<sup>®</sup>, INVEGA SUSTENNA<sup>®</sup>, INVEGA TRINZA<sup>®</sup>, TREVICTA<sup>®</sup>, and XEPLION<sup>®</sup> that are not included in the company's FY'22 financial expectations. This revenue was excluded from the company's FY'22 financial expectations for financial planning purposes due to the partial termination by Janssen of a license agreement with the company related to royalties from these products beginning in the U.S. after January 2022. The company has not received a notice of termination from Janssen in respect of any markets outside the U.S. However, for financial planning purposes only, the company has decided to remove all royalties related to sales in markets outside the U.S. after May 2022. Alkermes continues to disagree with the position taken by Janssen and is prepared to pursue all options at its disposal to enforce its contractual rights and address any unauthorized use of its intellectual property.

